GlucoTrack, Inc. Announces 2023 Annual Meeting of Stockholders on April 26, 2024
Ticker: GCTK · Form: DEF 14A · Filed: Apr 1, 2024 · CIK: 1506983
| Field | Detail |
|---|---|
| Company | Glucotrack, INC. (GCTK) |
| Form Type | DEF 14A |
| Filed Date | Apr 1, 2024 |
| Risk Level | medium |
| Pages | 16 |
| Reading Time | 19 min |
| Key Dollar Amounts | $0.001, $750,000, $500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: Annual Meeting, Proxy Statement, Reverse Stock Split, Equity Incentive Plan, Executive Compensation
TL;DR
<b>GlucoTrack, Inc. is holding its 2023 Annual Meeting on April 26, 2024, to vote on equity plans, director elections, a reverse stock split, auditor ratification, and executive compensation frequency.</b>
AI Summary
GlucoTrack, Inc. (GCTK) filed a Proxy Statement (DEF 14A) with the SEC on April 1, 2024. The 2023 Annual Meeting of Stockholders for GlucoTrack, Inc. will be held on April 26, 2024. Key proposals include adopting the 2024 Equity Incentive Plan and electing six director nominees. Stockholders will vote on a reverse stock split with a ratio between 1-for-5 and 1-for-30. The appointment of Fahn Kanne & Co. as independent auditor for fiscal year 2023 will be ratified. A vote on the frequency of advisory votes on executive compensation (1, 2, or 3 years) is also scheduled.
Why It Matters
For investors and stakeholders tracking GlucoTrack, Inc., this filing contains several important signals. The proposed reverse stock split could significantly alter the company's share structure and potentially impact its stock price and marketability. The outcome of the votes on the equity incentive plan and director elections will shape the company's future leadership and employee compensation strategies.
Risk Assessment
Risk Level: medium — GlucoTrack, Inc. shows moderate risk based on this filing. The company is proposing a reverse stock split, which can be a sign of financial distress or an attempt to meet exchange listing requirements, indicating potential underlying issues.
Analyst Insight
Stockholders should carefully review the details of the proposed reverse stock split and equity incentive plan before voting at the Annual Meeting.
Key Numbers
- April 26, 2024 — Annual Meeting Date (2023 Annual Meeting of Stockholders)
- 1-for-5 to 1-for-30 — Reverse Stock Split Ratio (Ratio to be determined by the Board)
- 2024 — Equity Plan Year (2024 Equity Incentive Plan)
- 2023 — Fiscal Year (Independent registered public accounting firm for the fiscal year ended December 31, 2023)
- 1, 2, or 3 — Executive Compensation Vote Frequency (Frequency of non-binding advisory votes)
Key Players & Entities
- GlucoTrack, Inc. (company) — Registrant
- April 26, 2024 (date) — Date of Annual Meeting
- Erin Carter (person) — Director Nominee
- Allen Danzig (person) — Director Nominee
- Robert Fischell (person) — Director Nominee
- Luis Malave (person) — Director Nominee
- Shimon Rapps (person) — Director Nominee
- Andrew Sycoff (person) — Director Nominee
FAQ
When did GlucoTrack, Inc. file this DEF 14A?
GlucoTrack, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 1, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by GlucoTrack, Inc. (GCTK).
Where can I read the original DEF 14A filing from GlucoTrack, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by GlucoTrack, Inc..
What are the key takeaways from GlucoTrack, Inc.'s DEF 14A?
GlucoTrack, Inc. filed this DEF 14A on April 1, 2024. Key takeaways: The 2023 Annual Meeting of Stockholders for GlucoTrack, Inc. will be held on April 26, 2024.. Key proposals include adopting the 2024 Equity Incentive Plan and electing six director nominees.. Stockholders will vote on a reverse stock split with a ratio between 1-for-5 and 1-for-30..
Is GlucoTrack, Inc. a risky investment based on this filing?
Based on this DEF 14A, GlucoTrack, Inc. presents a moderate-risk profile. The company is proposing a reverse stock split, which can be a sign of financial distress or an attempt to meet exchange listing requirements, indicating potential underlying issues.
What should investors do after reading GlucoTrack, Inc.'s DEF 14A?
Stockholders should carefully review the details of the proposed reverse stock split and equity incentive plan before voting at the Annual Meeting. The overall sentiment from this filing is neutral.
Risk Factors
- Reverse Stock Split [medium — financial]: The company proposes a reverse stock split to potentially increase the per-share market price of its common stock, with the ratio determined by the Board.
- 2024 Equity Incentive Plan [low — financial]: Adoption of a new equity incentive plan to provide for the grant of stock options, restricted stock, and other equity-based awards to employees and directors.
- Frequency of Advisory Votes on Executive Compensation [low — regulatory]: Stockholders will vote on whether advisory votes on executive compensation should occur every one, two, or three years.
Key Dates
- 2024-04-26: 2023 Annual Meeting of Stockholders — To vote on key corporate matters including equity plans, director elections, and a reverse stock split.
Filing Stats: 4,813 words · 19 min read · ~16 pages · Grade level 12.1 · Accepted 2024-04-01 15:49:16
Key Financial Figures
- $0.001 — Company’s common stock, par value $0.001 per share (“Common Stock”)
- $750,000 — ny non-employee director may not exceed $750,000 for the first calendar year a non-emplo
- $500,000 — Company’s Board of Directors, and $500,000 in any other calendar year. Types of
Filing Documents
- formdef14a.htm (DEF 14A) — 811KB
- 0001493152-24-012324.txt ( ) — 813KB
From the Filing
DEF 14A 1 formdef14a.htm UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to Rule 14a-12 GLUCOTRACK, INC. (Name of Registrant as Specified in its Charter) N/A (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (check the appropriate box): No fee required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 GLUCOTRACK, INC. 301 Route 17 North, Ste. 800 Rutherford, NJ 07070 (201) 842-7715 NOTICE OF 2023 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON APRIL 26, 2024 To the Stockholders of GlucoTrack, Inc: The 2023 Annual Meeting of Stockholders (the “Annual Meeting”) of GlucoTrack, Inc., a Delaware corporation (the “Company”), will be held on April 26, 2024 at 10:00 a.m., Eastern Time, at www.virtualshareholdermeeting.com/GCTK2024 , for the following purposes: 1. To adopt the Company’s 2024 Equity Incentive Plan; 2. To elect each of Erin Carter, Allen Danzig, Robert Fischell, Luis Malave, Shimon Rapps and Andrew Sycoff (the “Director Nominees”) to serve on the Board of Directors (the “Board”) for a one-year term that expires at the 2024 Annual Meeting of Stockholders, or until their earlier death, resignation or removal and their successors are elected and qualified; 3. To approve an amendment to Article IV of the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Amended and Restated Certificate of Incorporation”) to effect a reverse stock split of the Company’s common stock, par value $0.001 per share (“Common Stock”) at a ratio of between one-for-five and one-for-thirty, with such ratio to be determined at the sole discretion of the Board (the “Reverse Stock Split”) and with such Reverse Stock Split to be effected at such time and date, if at all, as determined by the Board in its sole discretion; 4. To ratify the previous appointment by the Audit Committee of the Board of Fahn Kanne & Co. as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2023; 5. To vote on the frequency of non-binding advisory votes regarding the executive compensation of named executive officers, every one (1), two (2) or three (3) years; and 6. To transact such other business as may properly come before the Annual Meeting or any adjournment thereof. The Board unanimously recommends a vote “FOR” each of Proposal 1, Proposal 3, and Proposal 4, a vote “FOR” the approval of each of the Director Nominees in Proposal 2 and a vote for “THREE YEARS” for Proposal 5. Pursuant to our Bylaws, our Board has fixed the close of business on February 26, 2024 as the record date (the “Record Date”) for a determination of stockholders entitled to notice and to vote at the Annual Meeting and any adjournment thereof. Holders of our Common Stock are entitled to vote at the Annual Meeting. In the event that there are insufficient shares present in person or represented by proxy at the Annual Meeting in order to obtain a quorum, the Annual Meeting may be adjourned or postponed in order to permit further solicitation of proxies. The Annual Meeting will be held as a virtual meeting via live webcast on the Internet on Friday, April 26, 2024, at 10 a.m. Eastern Time. Because the meeting is completely virtual and being conducted via the Internet, stockholders will not be able to attend the meeting in person. Shareholders may participate in the Annual Meeting by visiting the following website: www.virtualshareholdermeeting.com/GCTK2024 . To participate in the Annual Meeting, you will need the 16-digit control number included on your proxy card or on the instructions that accompanied your proxy materials. Shares held in your name as the shareholder of record may be voted electronically during the Annual Meeting. Shares for which you are the beneficial owner but not the shareholder of record also may be voted electronically during the Annual Meeting. However, even if you plan to attend the Annual Meeting, the Company recommends that you vote your shares in advance, so that your vote will be counted if you later decide not to attend the Annual Meeting. The accompanying proxy statement is dated April 1, 2024, and is first being mailed to stockholders of the Company on or about April 2, 2024. By Order of the Board of Directors, Paul V. Goode, PhD, Chief Executive Off